Search Within

Brian Kushner

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (38)
  2. Meeting Abstract (15)
  3. Conference Paper (2)
Groups
  1. Epidemiology and Biostatistics (55)
  2. Neuroblastoma Service (55)
  3. Pediatrics, Department of (55)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (52)
  5. GSK Faculty (52)
  6. Tow Center for Developmental Oncology (TCDO) (52)

More Groups

People
  1. Nai-Kong Cheung (50)
  2. Shakeel Modak (33)
  3. Kim Kramer (28)
  4. Irene Cheung (21)
  5. Ellen Basu (20)
  6. Stephen Roberts (18)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (3)
  5. 2021 (4)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Pediatric Blood and Cancer (13)
  3. Cancer (5)
  4. Cancer Research (3)
  5. Medical and Pediatric Oncology (3)
  6. OncoImmunology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. Wiley Periodicals, Inc (13)
  3. American Association for Cancer Research (5)
  4. Wiley Blackwell (5)
  5. Landes Bioscience (3)
  6. Wiley Liss (3)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of oral yeast-derived β-glucan to enhance anti-GD2 immunotherapy of resistant high-risk neuroblastoma
    Journal Article

    Iglesias Cardenas, F.; Mauguen, A.; Cheung, I. Y.; Kramer, K.; Kushner, B. H.; Ragupathi, G.; Cheung, N. K. V.; Modak, S.
    Cancers (2021)

    Fulltext@MSK | Save
  • Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma
    Meeting Abstract

    Shahid, S.; Kushner, B.; Modak, S.; Basu, E.; Rubin, E.; Gundem, G.; Papaemmanuil, E.; Roberts, S.
    Pediatric Blood and Cancer (2021)

    Fulltext@MSK | Save
  • Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma
    Journal Article

    Shahid, S.; Kushner, B. H.; Modak, S.; Basu, E. M.; Rubin, E. M.; Gundem, G.; Papaemmanuil, E.; Roberts, S. S.
    Pediatric Blood and Cancer (2021)

    Fulltext@MSK | Save
  • Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression
    Journal Article

    Cheung, I. Y.; Cheung, N. K. V.; Modak, S.; Mauguen, A.; Feng, Y.; Basu, E.; Roberts, S. S.; Ragupathi, G.; Kushner, B. H.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Survival impact of anti-GD2 antibody response - A phase II ganglioside vaccine trial in relapsed neuroblastoma
    Meeting Abstract

    Cheung, I. Y.; Cheung, N. K. V.; Modak, S.; Mauguen, A.; Basu, E.; Roberts, S. S.; Ragupathi, G.; Kushner, B. H.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Focal nodular hyperplasia in survivors of childhood cancer
    Meeting Abstract

    Considine, C.; Do, K. G.; Moskowitz, C.; Tonorezos, E.; Behr, G.; Diotallevi, D.; Candela, J.; Kushner, B.; Wexler, L.; Boulad, F.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor for neuroblastoma: Outpatient treament low immunogenicity, and major responses in a phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for relapsed neuroblastoma resistant to salvage therapy: A phase II trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for consolidating >= 2nd complete remission of high-risk neuroblastoma
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Cheung, N. K.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save